Nassim El Hajj, M.D.
Dr Elhajj received his Internal Medicine degree from Staten Island University Hospital, in Staten Island New York, and completed his gastroenterology fellowship at SUNY Downstate Medical Center, Brooklyn, New York. Dr Elhajj joined our practice in 2008.
Office locations
Practicing since
2008
Certifications
- USMLE Step I, 1999
- USMLE Step II, 2000
- USMLE Step III, 2001
- Permanent ECFMG Certificate, 2000
National Provider Identifier
1073719688
Professional Clinical Positions
| 2008 - Present | Borland-Groover Clinic, P.A. | Jacksonville, Florida |
Medical Education
| 1994 - 2000 | Faculty of Medical Sciences, Lebanese University |
| 2000 | Medical Diploma, Lebanese University |
Postgraduate Education
| 2005 - 2008 | Fellow, Gastroenterology and Hepatology, SUNY Downstate Medical Center | Brooklyn, New York |
| 2004 - 2005 | Chief Medical Resident, Staten Island University Hospital | Staten Island, New York |
| 2001 - 2004 | Internal Medicine, Staten Island University Hospital | Staten Island, New York |
Publications
Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transplantation Volume 12, Issue 5, Date: May 2006, Pages: 827-830
The development of DE NOVO autoimmune hepatitis (immune-mediated hepatitis) and its effect on outcome in patients with HCV post liver transplantation. Hepatology, Volume 44, Issue S1 (p 414A), Abstract # 606
Abstracts
The development of DE NOVO autoimmune hepatitis (immune-mediated hepatitis) and its effect on outcome in patients with HCV post liver transplantation. Poster presentation - AASLD meeting - Boston October 2006
The Risk of Acute Rejection in Patients Treated with Pegylated Interferon and Ribavirin for Recurrent Hepatitis C Post Liver Transplantation. Poster presentation - Digestive Disease Week - New Orleans May 2004
Improved Efficacy and Tolerability in Treating Post-Transplant HCV Utilizing an Escalating Regimen of Pegylated Interferon a-2a and Ribavirin with Hematopoietic Growth Factors: A Prospective Study. Oral presentation - Digestive Disease Week - New Orleans May 2004
Switching from Peg-Interferon a-2b to an escalating Peg-Interferon a-2a Regimen for recurrent Hepatitis C Post Liver Transplantation may Improve Virological Response and Tolerability. Poster presentation - Digestive Disease Week - New Orleans May 2004